The study evaluates a new second-generation assay for measuring basal serum calcitonin (CT) in diagnosing and monitoring medullary thyroid carcinoma (MTC), suggesting it may be a viable alternative to the pentagastrin-stimulation test.
A total of 162 patients, including those with RET proto-oncogene mutations and postoperative follow-up cases, participated, with measurements taken for both basal and Pg-stimulated CT levels.
Results showed that while the new assay has high specificity and reduces false negatives compared to older methods, its sensitivity for detecting C-cell disease is still lower than that provided by the Pg-stimulation test.